We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

9 hedge funds and large institutions have $156K invested in ABVC BioPharma in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% more ownership

Funds ownership: 1.83% → 1.84% (+0.01%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

9% less capital invested

Capital invested by funds: $171K → $156K (-$14.7K)

18% less funds holding

Funds holding: 11 → 9 (-2)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
9
Holders Change
-2
Holders Change %
-18.18%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$11.8K
2
TSS
Two Sigma Securities
New York
+$8.95K
3
XT
XTX Topco
Cayman Islands
+$3.22K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$19.5K
2
Bank of America
Bank of America
North Carolina
-$128
3
TRCT
Tower Research Capital (TRC)
New York
-$17

ABVC Hedge Fund Activity: Q3 2024 in Review

9 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q3 2024, worth a combined $156K — down 8.6% from $171K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ABVC and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $11.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $19.5K sold.

  • 9 institutional investors held ABVC BioPharma (ABVC) as of Q3 2024, down from 11 in Q2 2024.
  • Funds reported $156K of ABVC BioPharma stock for Q3 2024, down 8.6% quarter-over-quarter.
  • 1 fund opened new ABVC BioPharma positions in Q3 2024 and 2 closed out, a net change of -1 holder.
  • The largest ABVC BioPharma buyer in Q3 2024 was Geode Capital Management, an estimated $11.8K added.
  • The largest ABVC BioPharma seller in Q3 2024 was Citadel Advisors, an estimated $19.5K sold.

Based on aggregated 13F filings for Q3 2024.